biote Corp. Files 8-K on Operations & Financial Condition
Ticker: BTMD · Form: 8-K · Filed: Jan 17, 2024 · CIK: 1819253
Complexity: simple
Sentiment: neutral
Topics: financial-condition, regulation-fd, corporate-update
TL;DR
**biote Corp. just dropped an 8-K on its financials, stay tuned for details.**
AI Summary
biote Corp. filed an 8-K on January 17, 2024, to report on its results of operations and financial condition, as well as Regulation FD Disclosure. This filing, under SEC File Number 001-40128, indicates that the company is providing current information to the market. For investors, this matters because it signals that biote Corp. is actively communicating its financial health and operational status, which can influence stock performance (BTMD) and investment decisions.
Why It Matters
This filing provides updated information on biote Corp.'s financial performance and operational status, which is crucial for investors to assess the company's health and make informed decisions about their BTMD stock.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial and operational updates, not indicating any immediate high-risk events.
Analyst Insight
A smart investor would monitor biote Corp.'s upcoming financial releases for the specific details hinted at in this 8-K, as this filing itself is primarily a procedural announcement of intent to disclose.
Key Numbers
- 001-40128 — SEC File Number (Identifies biote Corp.'s registration with the SEC)
- 20240117 — Filing Date (Indicates when the information was officially submitted to the SEC)
Key Players & Entities
- biote Corp. (company) — the registrant filing the 8-K
- 001-40128 (dollar_amount) — SEC File Number for biote Corp.
- January 17, 2024 (date) — Date of earliest event reported and filing date
- BTMD (company) — Trading symbol for biote Corp. Class A common stock
- The Nasdaq Stock Market LLC (company) — Exchange where biote Corp. Class A common stock is registered
Forward-Looking Statements
- biote Corp. will likely release more detailed financial statements or an earnings report soon, following this disclosure of 'Results of Operations and Financial Condition'. (biote Corp.) — medium confidence, target: Q1 2024
FAQ
What is the primary purpose of biote Corp.'s 8-K filing on January 17, 2024?
The primary purpose of biote Corp.'s 8-K filing on January 17, 2024, is to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure', as stated in the 'ITEM INFORMATION' section of the filing.
What is biote Corp.'s trading symbol and on which exchange is it registered?
biote Corp.'s trading symbol is 'BTMD' and its Class A common stock is registered on 'The Nasdaq Stock Market LLC', as detailed under 'Securities registered pursuant to Section 12(b) of the Act' in the filing.
What is the business address and phone number of biote Corp. as listed in the filing?
The business address for biote Corp. is '1875 W. Walnut Hill Ln #100 Irving, Texas 75038' and its business phone number is '(844) 604-1246', according to the 'BUSINESS ADDRESS' and 'BUSINESS PHONE' sections of the filing.
What was biote Corp.'s former company name and when did the name change occur?
biote Corp.'s former company name was 'Haymaker Acquisition Corp. III', and the date of the name change was '20200727', as indicated in the 'FORMER COMPANY' section of the filing.
What is the state of incorporation for biote Corp. and its IRS Employer Identification Number?
biote Corp. is incorporated in 'Delaware' and its I.R.S. Employer Identification No. is '85-1791125', as specified in the header information of the 8-K filing.
Filing Stats: 667 words · 3 min read · ~2 pages · Grade level 9.1 · Accepted 2024-01-17 16:39:35
Key Financial Figures
- $0.0001 — stered Class A common stock, par value $0.0001 per share BTMD The Nasdaq Stock Mar
Filing Documents
- d730565d8k.htm (8-K) — 25KB
- d730565dex991.htm (EX-99.1) — 17KB
- d730565dex992.htm (EX-99.2) — 10KB
- g730565g0117005827654.jpg (GRAPHIC) — 3KB
- g730565g0118013845338.jpg (GRAPHIC) — 3KB
- 0001193125-24-009293.txt ( ) — 191KB
- btmd-20240117.xsd (EX-101.SCH) — 3KB
- btmd-20240117_lab.xml (EX-101.LAB) — 18KB
- btmd-20240117_pre.xml (EX-101.PRE) — 11KB
- d730565d8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On January 17, 2024, biote Corp., a Delaware corporation (the "Company") issued a press release to report preliminary financial results for the three months and year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01
Item 7.01 Regulation FD Disclosure On January 17, 2024, the Company also issued a press release to announce that it has entered into an agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 7.01 and the attached Exhibit 99.2 are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Financial Results Press Release, dated January 17, 2024. 99.2 Press Release, dated January 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. biote Corp. By: /s/ Teresa S. Weber Name: Teresa S. Weber Title: Chief Executive Officer Date: January 17, 2024